Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

Data were derived from Walrave L, et al. Abstract 920: Mepolizumab is efficacious in patients with chronic rhinosinusitis with nasal polyps (CRSWNP) with one or multiple prior nasal polyps (NP ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD: Paris Wednesday, April 16, 2025, 10:00 Hrs [IST] Sanofi shared new pro ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Sanofi added that, in partnership with Regeneron, two phase 3 studies in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), CEREN 1 and CEREN 2 and one phase 2 study in patients with ...

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...